PVI is a payer-centered platform that supports a more consistent, transparent and efficient review of clinical, economic and patient-centered evidence. Watch a demo of the platform.
JMCP Outsert - CLL (BTKis)
Recommendations for treatment initiation in CLL are stratified by disease stage using either the Rai staging system, which defines disease as low-, intermediate-, or high-risk; or the Binet staging system, which defines disease as stage A, B, or C based on the number of lymphoid areas involved and the presence of anemia or thrombocytopenia. Generally, treatment should be initiated in patients with active or progressive disease who are intermediate- or high-risk, or stage B or C.
Related
AMCP's Q3 2026 Precision Medicine Bulletin is now available, featuring a recap of key precision medicine developments from 2026, a review of recent clinical guidelines, highlights from new publications in the field, and updates on AMCP's submission to the National Comprehensive Cancer Network (NCCN).
Pharmacy benefit manager (PBM) reform is evolving rapidly at the state level, creating a complex and often fragmented policy landscape that stakeholders must actively monitor. Understanding which reforms are advancing in each state is critical, as these policies can significantly alter drug pricing dynamics, rebate structures, formulary design, and patient access.
Featured News & Resources
See Full CalendarUpcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
